We would love to hear your thoughts about our site and services, please take our survey here.
IMHO the M3 update has done the damage
A change in the dose formulation will no doubt lead to a renewed phase 2 study.
How much funding will DEST be required to contribute to this new phase 2.
Phase 3 now looks at least 2 years away
Aimho
Dr Bill Love, Chief Scientific Officer of Destiny Pharma said: "I would like to thank NIAID for their support and collaboration throughout the preclinical safety study in XF-73 Dermal and I am delighted to announce this positive dataset.
Independent Technical Report gives unrisked P50 and P10 Contingent recoverable gas resources of 109.28 and 234.42 BCF respectively net to PRD.
· Unrisked P50 and P10 Prospective recoverable gas resources of 139.67 and 312.16 BCF respectively net to PRD.
Keith why the huge difference in the numbers apart from the ITR using contingent